Full Text
EE649 Requirements for Payer Recognition of Disease-Modifying Effect in New Drug Launches

Abstract

Authors

Richard Mee

Back to Volume 28, Supplemental Issue 12S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×